AngioLab Inc
251280
Company Profile
Business description
AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.
Contact
65 Techno 3ro
Suite 159
Hanshin S Mecca
Yuseong-gu
Doejeon
CHNT: +86 428675785
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
16
Stocks News & Analysis
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
stocks
Bookworm: Is this the secret to exceptional long-term returns?
Acceptance may be an investor’s best friend.
stocks
Unconventional wisdom: Are dividends the answers?
As investors toil in complexity the obvious solution may be the right one.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,962.80 | 28.50 | 0.32% |
| CAC 40 | 7,834.58 | 16.30 | 0.21% |
| DAX 40 | 24,217.50 | 78.43 | -0.32% |
| Dow JONES (US) | 44,901.92 | 208.01 | 0.47% |
| FTSE 100 | 9,120.31 | 18.06 | -0.20% |
| HKSE | 25,519.91 | 131.56 | 0.52% |
| NASDAQ | 21,108.32 | 50.36 | 0.24% |
| Nikkei 225 | 41,003.40 | 452.83 | -1.09% |
| NZX 50 Index | 12,910.74 | 57.28 | 0.45% |
| S&P 500 | 6,388.64 | 25.29 | 0.40% |
| S&P/ASX 200 | 8,698.60 | 31.70 | 0.37% |
| SSE Composite Index | 3,595.13 | 1.48 | 0.04% |